Vertex Pharmaceuticals, Inc. (VRTX)
538.60
-4.02
(-0.74%)
USD |
NASDAQ |
Nov 13, 16:00
535.92
-2.68
(-0.50%)
After-Hours: 19:59
Vertex Pharmaceuticals Price to Book Value : 6.531 for Nov. 13, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 6.531 |
| November 12, 2026 | 6.580 |
| November 11, 2026 | 6.633 |
| November 10, 2026 | 6.644 |
| November 09, 2026 | 6.680 |
| November 06, 2026 | 6.634 |
| November 05, 2026 | 6.578 |
| November 04, 2026 | 6.658 |
| November 03, 2026 | 6.436 |
| November 02, 2026 | 6.708 |
| October 30, 2026 | 6.777 |
| October 29, 2026 | 6.548 |
| October 28, 2026 | 6.423 |
| October 27, 2026 | 6.318 |
| October 26, 2026 | 6.275 |
| October 23, 2026 | 6.353 |
| October 22, 2026 | 6.490 |
| October 21, 2026 | 6.360 |
| October 20, 2026 | 6.241 |
| October 19, 2026 | 6.087 |
| October 16, 2026 | 6.060 |
| October 15, 2026 | 6.169 |
| October 14, 2026 | 6.045 |
| October 13, 2026 | 5.884 |
| October 12, 2026 | 6.148 |
| Date | Value |
|---|---|
| October 09, 2026 | 6.185 |
| October 08, 2026 | 6.102 |
| October 07, 2026 | 6.131 |
| October 06, 2026 | 6.091 |
| October 05, 2026 | 6.105 |
| October 02, 2026 | 6.120 |
| October 01, 2026 | 6.145 |
| September 30, 2026 | 6.340 |
| September 29, 2026 | 6.591 |
| September 28, 2026 | 6.602 |
| September 25, 2026 | 6.584 |
| September 24, 2026 | 6.536 |
| September 23, 2026 | 6.461 |
| September 22, 2026 | 6.444 |
| September 21, 2026 | 6.390 |
| September 18, 2026 | 6.360 |
| September 17, 2026 | 6.461 |
| September 16, 2026 | 6.422 |
| September 15, 2026 | 6.439 |
| September 14, 2026 | 6.500 |
| September 11, 2026 | 6.449 |
| September 10, 2026 | 6.438 |
| September 09, 2026 | 6.520 |
| September 08, 2026 | 6.618 |
| September 04, 2026 | 6.833 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Alnylam Pharmaceuticals, Inc. | 6.131 |
| Gilead Sciences, Inc. | 16.00 |
| Regeneron Pharmaceuticals, Inc. | 2.949 |
| Amgen, Inc. | 17.55 |
| TG Therapeutics, Inc. | 17.04 |
Price to Book Value Related Metrics
| PE Ratio | 34.65 |
| PS Ratio | 10.58 |
| PEG Ratio | 3.623 |
| Price to Free Cash Flow | 43.01 |
| Price | 538.60 |
| Earnings Yield | 2.89% |
| Market Cap | 136.55B |
| PEGY Ratio | 3.623 |
| Operating PE Ratio | 30.26 |
| Normalized PE Ratio | 33.58 |